BGB-11417, BGB-11417 placebo, BGB-11417, BGB-11417, BGB-11417, Zanubrutinib
BGB-11417-302
Phase 3 small_molecule active
Quick answer
BGB-11417, BGB-11417 placebo, BGB-11417, BGB-11417, BGB-11417, Zanubrutinib for relapsed or refractory mantle cell lymphoma (R/R MCL) is a Phase 3 program (small_molecule) at Beone Medicines Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beone Medicines Ireland Limited
- Indication
- relapsed or refractory mantle cell lymphoma (R/R MCL)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active